Advertisement
Advertisement
GOSS
Gossamer Bio, Inc. Common Stock
0.18
USDSponsored
0.00
-0.22%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
0.18
0.00
+0.56%
GOSS Earnings Reports
Positive Surprise Ratio
GOSS beat 14 of 30 last estimates.
47%
Next Report
Tomorrow BMO
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$5.30M
/-$0.12
Implied change from Q1 26 (Revenue/ EPS)
-68.76%
/-40.00%
Implied change from Q2 25 (Revenue/ EPS)
-53.89%
/-29.41%
Gossamer Bio, Inc. Common Stock earnings per share and revenue
On May 15, 2026, GOSS reported earnings of -0.20 USD per share (EPS) for Q1 26, missing the estimate of -0.16 USD, resulting in a -18.62% surprise. Revenue reached 16.95 million, compared to an expected 5.58 million, with a 204.05% difference. The market reacted with a -3.96% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 5.30 million USD, implying an decrease of -40.00% EPS, and decrease of -68.76% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Corvus Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-17.36%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Ligand Pharmaceuticals Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.90
Actual
$2.37
Surprise
+24.56%
Trevi Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+2.22%
FAQ
What were Gossamer Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Gossamer Bio, Inc. Common Stock reported EPS of -$0.20, missing estimates by -18.62%, and revenue of $16.95M, 204.05% above expectations.
How did the market react to Gossamer Bio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -3.96%, changed from $0.34 before the earnings release to $0.33 the day after.
When is Gossamer Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Gossamer Bio, Inc. Common Stock's next earnings report?
Based on 7
analysts, Gossamer Bio, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $5.30M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement